- PLN290.92m
- PLN266.29m
- PLN151.68m
- 49
- 76
- 64
- 71
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 30.48 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | -72.12% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.15 | ||
Price to Tang. Book | 2.16 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.99 | ||
EV to EBITDA | 4.6 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 29.69% | ||
Return on Equity | 37.09% | ||
Operating Margin | 34.61% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | PLNm | n/a | n/a | 56.87 | 163.98 | 151.68 | 112.63 | 111.3 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | +945.69 | +121.38 | -76.94 | -45.32 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Directors
- Dirk Kreder PRE
- Jolanta Baranowska CAO
- Grzegorz Grabowicz MGB
- Slawomir Jaros MGB
- David James IND
- Robert Konski IND (53)
- Jozef Banach SUB
- Slawomir Kosciak SUB
- Zofia Szewczuk SUB
- Wojciech Wosko SUB
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 29th, 2009
- Public Since
- August 10th, 2010
- No. of Employees
- 226
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 16,162,326
- Address
- gen. Mariana Langiewicza 60, KONSTANTYNOW LODZKI, 95-050
- Web
- https://www.mabion.eu/
- Phone
- +48 422077890
- Contact
- Marek Bugdol
- Auditors
- PricewaterhouseCoopers Polska sp. z o.o. Audyt sp.k.
Upcoming Events for MAB
Half Year 2024 Mabion SA Earnings Release
Q3 2024 Mabion SA Earnings Release
Similar to MAB
Airway Medix SA
Warsaw Stock Exchange
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
E-Shopping SA
Warsaw Stock Exchange
FAQ
As of Today at 21:54 UTC, shares in Mabion SA are trading at PLN18.00. This share price information is delayed by 15 minutes.
Shares in Mabion SA last closed at PLN18.00 and the price had moved by -0.73% over the past 365 days. In terms of relative price strength the Mabion SA share price has underperformed the FTSE Global All Cap Index by -13.05% over the past year.
The overall consensus recommendation for Mabion SA is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Mabion SA does not currently pay a dividend.
Mabion SA does not currently pay a dividend.
Mabion SA does not currently pay a dividend.
To buy shares in Mabion SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN18.00, shares in Mabion SA had a market capitalisation of PLN290.92m.
Here are the trading details for Mabion SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: MAB
Based on an overall assessment of its quality, value and momentum Mabion SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mabion SA is PLN15.75. That is 12.5% below the last closing price of PLN18.00.
Analysts covering Mabion SA currently have a consensus Earnings Per Share (EPS) forecast of PLN0.74 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mabion SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -19.64%.
As of the last closing price of PLN18.00, shares in Mabion SA were trading +1.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mabion SA PE ratio based on its reported earnings over the past 12 months is 30.48. The shares last closed at PLN18.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mabion SA's management team is headed by:
- Dirk Kreder - PRE
- Jolanta Baranowska - CAO
- Grzegorz Grabowicz - MGB
- Slawomir Jaros - MGB
- David James - IND
- Robert Konski - IND
- Jozef Banach - SUB
- Slawomir Kosciak - SUB
- Zofia Szewczuk - SUB
- Wojciech Wosko - SUB